ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Gene therapy sustains bleeding control in haemophilia A trial
December 15, 2021Giroctocogene fitelparvovec had a mean annualised bleeding rate (ABR) of just 1.4 percent over two years, with no bleeding events in the first year post infusion. -
Pfizer, Sangamo announce updated results of phase 1/2 Alta study of giroctocogene fitelparvovec
December 09, 2020Pfizer and Sangamo Therapeutics, a genomic medicines company, announced updated follow-up data from the Phase 1/2 Alta study of giroctocogene fitelparvovec (SB-525 or PF-07055480), an investigational gene therapy for patients with severe hemophilia A.
Pharma Sources Insight January 2025
